Pathologic von Willebrand factor degradation with a left ventricular assist device occurs via two distinct mechanisms: Mechanical demolition and enzymatic.

Slides:



Advertisements
Similar presentations
Lost in translation The Journal of Thoracic and Cardiovascular Surgery
Advertisements

Manuel J. Antunes, MD, PhD, DSc 
Aortic valve replacement in low-flow, low-gradient aortic stenosis: Left ventricular ejection fraction matters  Victor Dayan, MD, PhD, Philippe Pibarot,
Long-term mechanical circulatory support: A new disease state?
Endoscopic Robotic Mitral Valve Surgery
Insights into the mechanism(s) of von Willebrand factor degradation during mechanical circulatory support  Carlo R. Bartoli, MD, PhD, Sujith Dassanayaka,
Increased cyclic guanosine monophosphate levels and continuous-flow left-ventricular assist devices: Implications for gastrointestinal bleeding  Liza.
Left Ventricular Assist Device Design Reduces von Willebrand Factor Degradation: A Comparative Study Between the HeartMate II and the EVAHEART Left Ventricular.
Martin Strueber, MD, Anna L
The days of future past  Neel K. Ranganath, MD, Aubrey C. Galloway, MD 
Personalized cardiac surgery: Can noninvasive flow imaging lead to individualized resection strategies for bicuspid aortopathy?  Nicholas D. Andersen,
Effects on pre- and posttransplant pulmonary hemodynamics in patients with continuous-flow left ventricular assist devices  Ranjit John, MD, Kenneth Liao,
Elucidating the intricate mechanisms of gastrointestinal bleeding in a continuous-flow left ventricular assist device will lead to future therapeutic.
Form ever follows function
Victor van Berkel, MD, PhD 
Multilevel data analysis: What? Why? How?
Definition of postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass: One size doesn't fit all  David Faraoni, MD,
Go on-pump or off-pump in diabetic patients?
New treatment approaches create new disease processes: A short guide on how to reduce unexpected events to a minimum  Martin Czerny, MD, MBA  The Journal.
Resuscitation practices in cardiac surgery
Intra-aortic balloon pump therapy negatively affects flow through a continuous-flow left ventricular assist device  Dipanjan Banerjee, MD, MS, Chun Choi,
Bigger The Journal of Thoracic and Cardiovascular Surgery
The lord of the rings  Antonio Miceli, MD, PhD 
Clinical and In Vitro Evidence That Subclinical Hemolysis Contributes to LVAD Thrombosis  Carlo R. Bartoli, MD, PhD, David Zhang, BSE, Jooeun Kang, BA,
Reduced continuous-flow left ventricular assist device speed does not decrease von Willebrand factor degradation  Jooeun Kang, BA, David M. Zhang, David.
Arman Kilic, MD, Pavan Atluri, MD 
Conduit conundrum: If not two, why three?
Expanding left ventricular assist device use to patients with disabilities: The role of assistive technology  Juan A. Crestanello, MD  The Journal of.
Kyle W. Riggs, MD, David L.S. Morales, MD 
Intra-aortic balloon pumps and continuous flow left ventricular assist devices: Don't let balloon pumps overstay their welcome  Kevin G. Soucy, PhD, Steven.
Adverse events in contemporary continuous-flow left ventricular assist devices: A multi- institutional comparison shows significant differences  John M.
Left ventricular assist device therapy in a patient with hearing and speech disabilities  Sotirios Spiliopoulos, MD, PhD, Vera Hergesell, MD, Otto Dapunt,
Michael Mack, MD, David Taggart, MD 
It's not “just a shunt” but sometimes it should be…
Do we need a bibliometrician to know which way the wind is blowing?
A first start for lung transplantation?
Right ventricular failure after cardiac surgery: Why can't right ventricular assist device support fix the problem?  Francis D. Pagani, MD, PhD  The Journal.
William L. Holman, MD, James K. Kirklin, MD, David C
Assessment of platelet function with light transmission aggregometry in 24 patients supported with a continuous-flow left ventricular assist device: A.
Joseph A. Dearani, MD, Michael J. Ackerman, MD, PhD 
Jennifer J. Chung, MD, Jonathan Gordon, BA, Pavan Atluri, MD 
Jeevanantham Rajeswaran, PhD, Eugene H. Blackstone, MD 
Leora B. Balsam, MD, Abe DeAnda, MD 
Attachment disorder in thoracoabdominal surgery
The Ross procedure: Time to reevaluate the guidelines
Video-assisted resection for lung cancer results in fewer complications  Lunxu Liu, PhD, MD, FRCS  The Journal of Thoracic and Cardiovascular Surgery 
Passing the torch The Journal of Thoracic and Cardiovascular Surgery
Prognosis and “granularity”: Building on staging foundations?
Patients with unbalanced atrioventricular canal defects can undergo the Fontan operation with good outcomes  Sitaram M. Emani, MD  The Journal of Thoracic.
Functional tricuspid pathology: To treat or not to treat
Left ventricular assist device implantation after acute anterior wall myocardial infarction and cardiogenic shock: A two-center study  Nicholas C. Dang,
The harder one looks, the more one finds
Jason J. Han, MD, Pavan Atluri, MD 
The Journal of Thoracic and Cardiovascular Surgery
Discussion The Journal of Thoracic and Cardiovascular Surgery
The future of cardiac surgery training: A survival guide
Ventricular assistant in restrictive cardiomyopathy: Making the right connection  Robert D.B. Jaquiss, MD  The Journal of Thoracic and Cardiovascular Surgery 
Reliability of risk algorithms in predicting early and late operative outcomes in high-risk patients undergoing aortic valve replacement  Todd M. Dewey,
Cerebrovascular accidents in patients with a ventricular assist device
Seeing is believing: A call for routine early postoperative hemodynamic transesophageal echocardiography monitoring after left ventricular assist device.
“The more things change…”: The challenges ahead
Optimal timing for heart transplantation in patients bridged with left ventricular assist devices: Is timing of the essence?  Chase R. Brown, MD, Fabliha.
The evolution of cardiothoracic critical care
Of mice and men… The Journal of Thoracic and Cardiovascular Surgery
Gastrointestinal bleeding after left ventricular assist device implantation: It is all about the platelets  Juan A. Crestanello, MD  The Journal of Thoracic.
Did you like Terminator 3 better than Terminator 2
A good chimney requires a good sweep
How do we follow up our patients
Hari R. Mallidi, MD  The Journal of Thoracic and Cardiovascular Surgery 
The Journal of Thoracic and Cardiovascular Surgery
Presentation transcript:

Pathologic von Willebrand factor degradation with a left ventricular assist device occurs via two distinct mechanisms: Mechanical demolition and enzymatic cleavage  Carlo R. Bartoli, MD, PhD, David J. Restle, BSE, David M. Zhang, Michael A. Acker, MD, Pavan Atluri, MD  The Journal of Thoracic and Cardiovascular Surgery  Volume 149, Issue 1, Pages 281-289 (January 2015) DOI: 10.1016/j.jtcvs.2014.09.031 Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 A and B, The profile of vWF multimers and degradation fragments was determined in patients undergoing LVAD support. After LVAD support, agarose gel electrophoresis and immunoblotting for vWF revealed a decrease in large vWF multimers and an increase in small multimers compared with baseline (pre-LVAD). Polyacrylamide gel electrophoresis with immunoblotting revealed significantly increased vWF degradation fragments compared with baseline. C and D, An in vitro model was developed to reproduce the shear stress of a continuous-flow LVAD. Normal human blood exposed to supraphysiologic shear stress demonstrated the same profile of vWF multimers and vWF degradation fragments as patients with an LVAD. LVAD, Left ventricular assist device; vWF, von Willebrand factor; kDa, kilodalton. The Journal of Thoracic and Cardiovascular Surgery 2015 149, 281-289DOI: (10.1016/j.jtcvs.2014.09.031) Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 A, To investigate the specific mechanistic roles of shear stress and ADAMTS-13 (the vWF protease), purified vWF protein ± recombinant ADAMTS-13 protein were exposed to supraphysiologic shear stress. vWF multimers and degradation fragments were characterized with electrophoresis and immunoblotting. Exposure of purified vWF alone to supraphysiologic shear stress reduced large vWF multimers and increased small vWF multimers. However, vWF degradation fragments were not generated. In contrast, in the presence of ADAMTS-13, exposure to supraphysiologic shear stress completely eliminated large vWF multimers and significantly increased vWF degradation fragments. B and C, The pattern and quantity of vWF degradation fragments were different when vWF protein was exposed to supraphysiologic shear stress alone versus in the presence of ADAMTS-13 protease. D, In the presence of shear stress, the activity of ADAMTS-13 protein increased. ADAMTS-13, A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; vWF, von Willebrand factor; kDa, kilodalton. The Journal of Thoracic and Cardiovascular Surgery 2015 149, 281-289DOI: (10.1016/j.jtcvs.2014.09.031) Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 Supraphysiologic shear stress during LVAD support triggers globular (inactive) vWF to undergo a conformational elongation into an active form. Supraphysiologic shear stress alone physically demolishes large, active vWF multimers into smaller vWF multimers. In parallel, the major mechanism of vWF degradation with an LVAD is ADAMTS-13 cleavage of large, active vWF multimers into small, nonactive vWF fragments. As a result, an acquired vWF deficiency predisposes patients with an LVAD to bleeding events. ADAMTS-13, A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; LVAD, left ventricular assist device; vWF, von Willebrand factor. The Journal of Thoracic and Cardiovascular Surgery 2015 149, 281-289DOI: (10.1016/j.jtcvs.2014.09.031) Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions